Effects of nicotine on the neurophysiological and behavioral effects of ketamine in humans

Frontiers in Psychiatry

Volumn 5, Issue JAN, 2014, Pages

  Mathalon, Daniel H ^a,b   Ahn, Kyung Heup ^c,d,e   Perry, Edward B ^c,d,e   Cho, Hyun Sang ^c,f   Roach, Brian J ^b   Blais, Rebecca K ^c   Bhakta, Savita ^c   Ranganathan, Mohini ^c   Ford, Judith M ^a,b   D'Souza, Deepak Cyril ^c,d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^e Yale University School of Medicine   (United States)

^f Yonsei University College of Medicine   (South Korea)

Author keywords

Event related potential; Ketamine; Mismatch negativity; N methyl d aspartate receptor; Nicotine; Nicotinic acetylcholine receptor; P300; Schizophrenia

Indexed keywords

EID: 84893600766     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00003     Document Type: Article

References (141)

1. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci (2003) 1003:318-27. doi: 10.1196/annals.1300.020.
2. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry (1991) 148:1301-8.
3. Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull (2012) 38:958-66. doi:10.1093/schbul/sbs069.
4. Krystal JH, Anand A, Moghaddam B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry (2002) 59:663-4. doi:10.1001/archpsyc.59.7.663.
5. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) (2003) 169:215-33. doi:10.1007/s00213-003-1582-z.
6. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology (2012) 37:4-15. doi:10.1038/npp.2011.181.
7. Moghaddam B, Krystal JH. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull (2012) 38:942-9. doi:10.1093/schbul/sbs075.
8. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry (1998) 43:811-6. doi:10.1016/S0006-3223(97)00556-8.
9. Ahn KH, Youn T, Cho SS, Ha TH, Ha KS, Kim MS, et al. N-methyl-D-aspartate receptor in working memory impairments in schizophrenia: event-related potential study of late stage of working memory process. Prog Neuropsychopharmacol Biol Psychiatry (2003) 27:993-9. doi:10.1016/S0278-5846(03)00159-3.
10. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 51:199-214. doi:10.1001/archpsyc.1994.03950030035004.
11. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology (2001) 25:455-67. doi:10.1016/S0893-133X(01)00243-3.
12. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology (1996) 14:301-7. doi:10.1016/0893-133X(95)00137-3.
13. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology (2004) 29:208-18. doi:10.1038/sj.npp.1300342.
14. Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol (2004) 4:36-46. doi:10.1016/j.coph.2003.11.001.
15. Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry (2001) 49:258-67. doi:10.1016/S0006-3223(00)01094-5.
16. Swan GE, Lessov-Schlaggar CN. The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol Rev (2007) 17:259-73. doi:10.1007/s11065-007-9035-9.
17. Park S, Knopick C, McGurk S, Meltzer HY. Nicotine impairs spatial working memory while leaving spatial attention intact. Neuropsychopharmacology (2000) 22:200-9. doi:10.1016/S0893-133X(99)00098-6.
18. Sakurai Y, Kanazawa I. Acute effects of cigarettes in non-deprived smokers on memory, calculation and executive functions. Hum Psychopharmacol (2002) 17:369-73. doi:10.1002/hup.424.
19. George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology (2002) 26:75-85. doi:10.1016/S0893-133X(01)00296-2.
20. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev (2005) 29:1021-34. doi:10.1016/j.neubiorev.2005.02.006.
21. Sacco KA, Bannon KL, George TP. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol (2004) 18:457-74. doi:10.1177/0269881104047273.
22. Hetem LA, Danion JM, Diemunsch P, Brandt C. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology (Berl) (2000) 152:283-8. doi:10.1007/s002130000511.
23. Honey RA, Turner DC, Honey GD, Sharar SR, Kumaran D, Pomarol-Clotet E, et al. Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology (2003) 28:2037-44. doi:10.1038/sj.npp.1300272.
24. Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC, et al. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry (2000) 47:137-43. doi:10.1016/S0006-3223(99)00097-9.
25. Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology (2005) 30:633-9. doi:10.1038/sj.npp.1300642.
26. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry (2000) 57:1139-47. doi:10.1001/archpsyc.57.12.1139.
27. Polich J. Updating P300: an integrative theory of P3a and P3b. Clin Neurophysiol (2007) 118:2128-48. doi:10.1016/j.clinph.2007.04.019.
28. Isreal JB, Chesney GL, Wickens CD, Donchin E. P300 and tracking difficulty: evidence for multiple resources in dual-task performance. Psychophysiology (1980) 17:259-73. doi:10.1111/j.1469-8986.1980.tb00146.x.
29. Kramer AF, Strayer DL. Assessing the development of automatic processing: an application of dual-task and event-related brain potential methodologies. Biol Psychol (1988) 26:231-67. doi:10.1016/0301-0511(88)90022-1.
30. Ravden D, Polich J. Habituation of P300 from visual stimuli. Int J Psychophysiol (1998) 30:359-65. doi:10.1016/S0167-8760(98)00039-7.
31. Johnson R Jr, Donchin E. P300 and stimulus categorization: two plus one is not so different from one plus one. Psychophysiology (1980) 17:167-78. doi:10.1111/j.1469-8986.1980.tb00131.x.
32. Donchin E, Coles M. Is the P300 component a manifestation of context updating? (Commentary on Verleger's critique of the context updating model). Behav Brain Sci (1988) 11:357-74. doi:10.1017/S0140525X00058027.
33. Halgren E, Marinkovic K, Chauvel P. Generators of the late cognitive potentials in auditory and visual oddball tasks. Electroencephalogr Clin Neurophysiol (1998) 106:156-64. doi:10.1016/S0013-4694(97)00119-3.
34. Smith ME, Halgren E, Sokolik M, Baudena P, Musolino A, Liegeois-Chauvel C, et al. The intracranial topography of the P3 event-related potential elicited during auditory oddball. Electroencephalogr Clin Neurophysiol (1990) 76:235-48. doi:10.1016/0013-4694(90)90018-F.
35. Dien J, Spencer KM, Donchin E. Parsing the late positive complex: mental chronometry and the ERP components that inhabit the neighborhood of the P300. Psychophysiology (2004) 41:665-78. doi:10.1111/j.1469-8986.2004.00193.x.
36. Polich J, Kok A. Cognitive and biological determinants of P300: an integrative review. Biol Psychol (1995) 41:103-46. doi:10.1016/0301-0511(95)05130-9.
37. Spencer KM, Dien J, Donchin E. Spatiotemporal analysis of the late ERP responses to deviant stimuli. Psychophysiology (2001) 38:343-58. doi:10.1111/1469-8986.3820343.
38. Squires NK, Squires KC, Hillyard SA. Two varieties of long-latency positive waves evoked by unpredictable auditory stimuli in man. Electroencephalogr Clin Neuropysiol (1975) 38:387-401. doi:10.1016/0013-4694(75)90263-1.
39. Comerchero MD, Polich J. P3a, perceptual distinctiveness, and stimulus modality. Brain Res Cogn Brain Res (1998) 7:41-8. doi:10.1016/S0926-6410(98)00009-3.
40. Courchesne E, Hillyard S, Galambos R. Stimulus novelty, task relevance and the visual evoked potential in man. Electroencephalogr Clin Neurophysiol (1975) 39:131-43. doi:10.1016/0013-4694(75)90003-6.
41. Goldstein A, Spencer KM, Donchin E. The influence of stimulus deviance and novelty on the P300 and novelty P3. Psychophysiology (2002) 39:781-90. doi:10.1111/1469-8986.3960781.
42. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res (2004) 70:315-29. doi:10.1016/j.schres.2004.01.004.
43. Jeon YW, Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology (2003) 40:684-701. doi:10.1111/1469-8986.00070.
44. Charles G, Hansenne M. P 300 slow potential. Clinical interest in 3 mental diseases and neurobiology: a review. Encephale (1992) 18:225-236.
45. Hansenne M. The p300 cognitive event-related potential. II. Individual variability and clinical application in psychopathology. Neurophysiol Clin (2000) 30:211-31. doi:10.1016/S0987-7053(00)00224-0.
46. Gunduz-Bruce H, Reinhart RM, Roach BJ, Gueorguieva R, Oliver S, D'Souza DC, et al. Glutamatergic modulation of auditory information processing in the human brain. Biol Psychiatry (2012) 71:969-77. doi:10.1016/j.biopsych.2011.09.031.
47. Knott V, Millar AM, McIntosh JF, Shah DK, Fisher DJ, Blais CM, et al. Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention. Biol Psychol (2011) 88:83-93. doi:10.1016/j.biopsycho.2011.06.012.
48. Musso F, Brinkmeyer J, Ecker D, London MK, Thieme G, Warbrick T, et al. Ketamine effects on brain function-simultaneous fMRI/EEG during a visual oddball task. Neuroimage (2011) 58:508-25. doi:10.1016/j.neuroimage.2011.06.045.
49. Oranje B, Gispen-de Wied CC, Westenberg HG, Kemner C, Verbaten MN, Kahn RS. Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude. Int J Neuropsychopharmacol (2009) 12:823-32. doi:10.1017/S1461145708009814.
50. Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology (2000) 22:293-302. doi:10.1016/S0893-133X(99)00118-9.
51. Watson TD, Petrakis IL, Edgecombe J, Perrino A, Krystal JH, Mathalon DH. Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission. Int J Neuropsychopharmacol (2009) 12:357-70. doi:10.1017/S1461145708009334.
52. Naatanen R, Alho K. Mismatch negativity-a unique measure of sensory processing in audition. Int J Neurosci (1995) 80:317-37. doi:10.3109/00207459508986107.
53. Naatanen R, Gaillard AW, Mantysalo S. Early selective-attention effect on evoked potential reinterpreted. Acta Psychol (Amst) (1978) 42:313-29. doi:10.1016/0001-6918(78)90006-9.
54. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry (2006) 59:929-39. doi:10.1016/j.biopsych.2005.10.005.
55. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull (2009) 35:509-27. doi:10.1093/schbul/sbn176.
56. Garrido MI, Kilner JM, Stephan KE, Friston KJ. The mismatch negativity: a review of underlying mechanisms. Neurophysiol Clin (2009) 120:453-63. doi:10.1016/j.clinph.2008.11.029.
57. Naatanen R, Pakarinen S, Rinne T, Takegata R. The mismatch negativity (MMN): towards the optimal paradigm. Clin Neurophysiol (2004) 115:140-4. doi:10.1016/j.clinph.2003.04.001.
58. Michie PT. What has MMN revealed about the auditory system in schizophrenia? Int J Psychophysiol (2001) 42:177-94. doi:10.1016/S0167-8760(01)00166-0.
59. Todd J, Michie PT, Schall U, Karayanidis F, Yabe H, Naatanen R. Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biol Psychiatry (2008) 63:58-64. doi:10.1016/j.biopsych.2007.02.016.
60. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res (2005) 76:1-23. doi:10.1016/j.schres.2004.12.002.
61. Naatanen R, Kahkonen S. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int J Neuropsychopharmacol (2009) 12:125-35. doi:10.1017/S1461145708009322.
62. Umbricht D, Koller R, Schmid L, Skrabo A, Grubel C, Huber T, et al. How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry (2003) 53:1120-31. doi:10.1016/S0006-3223(02)01642-6.
63. Javitt DC, Steinschneider M, Schroeder CE, Arezzo JC. Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci U S A (1996) 93:11962-7. doi:10.1073/pnas.93.21.11962.
64. Javitt DC, Steinschneider M, Schroeder CE, Vaughan HG Jr, Arezzo JC. Detection of stimulus deviance within primate primary auditory cortex: intracortical mechanisms of mismatch negativity (MMN) generation. Brain Res (1994) 667:192-200. doi:10.1016/0006-8993(94)91496-6.
65. Heekeren K, Daumann J, Neukirch A, Stock C, Kawohl W, Norra C, et al. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl) (2008) 199:77-88. doi:10.1007/s00213-008-1129-4.
66. Knott V, Shah D, Millar A, McIntosh J, Fisher D, Blais C, et al. Nicotine, auditory sensory memory, and sustained attention in a human ketamine model of schizophrenia: moderating influence of a hallucinatory trait. Front Pharmacol (2012) 3:172. doi:10.3389/fphar.2012.00172.
67. Kreitschmann-Andermahr I, Rosburg T, Demme U, Gaser E, Nowak H, Sauer H. Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Brain Res Cogn Brain Res (2001) 12:109-16. doi:10.1016/S0926-6410(01)00043-X.
68. Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, et al. Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Neuropsychopharmacology (2012) 37:865-75. doi:10.1038/npp.2011.261.
69. Froeliger B, Gilbert DG, McClernon FJ. Effects of nicotine on novelty detection and memory recognition performance: double-blind, placebo-controlled studies of smokers and nonsmokers. Psychopharmacology (Berl) (2009) 205:625-33. doi:10.1007/s00213-009-1571-y.
70. Pineda JA, Herrera C, Kang C, Sandler A. Effects of cigarette smoking and 12-h abstention on working memory during a serial-probe recognition task. Psychopharmacology (Berl) (1998) 139:311-21. doi:10.1007/s002130050722.
71. Polich J, Criado JR. Neuropsychology and neuropharmacology of P3a and P3b. Int J Psychophysiol (2006) 60:172-85. doi:10.1016/j.ijpsycho.2005.12.012.
72. Pritchard W, Sokhadze E, Houlihan M. Effects of nicotine and smoking on event-related potentials: a review. Nicotine Tob Res (2004) 6:961-84. doi:10.1080/14622200412331324848.
73. Houlihan ME, Pritchard WS, Robinson JH. Effects of smoking/nicotine on performance and event-related potentials during a short-term memory scanning task. Psychopharmacology (Berl) (2001) 156:388-96. doi:10.1007/s002130100751.
74. Knott V, Bosman M, Mahoney C, Ilivitsky V, Quirt K. Transdermal nicotine: single dose effects on mood, EEG, performance, and event-related potentials. Pharmacol Biochem Behav (1999) 63:253-61. doi:10.1016/S0091-3057(99)00006-4.
75. Kodama E, Morita K, Kinoshita S, Miyahira A, Nakamura J, Maeda H. Inhibitory effect of smoking on event-related potentials in schizophrenic patients: comparison with healthy subjects. Prog Neuropsychopharmacol Biol Psychiatry (1998) 22:1275-88. doi:10.1016/S0278-5846(98)00082-7.
76. Edwards JA, Wesnes K, Warburton DM, Gale A. Evidence of more rapid stimulus evaluation following cigarette smoking. Addict Behav (1985) 10:113-26. doi:10.1016/0306-4603(85)90017-6.
77. Houlihan ME, Pritchard WS, Robinson JH. Faster P300 latency after smoking in visual but not auditory oddball tasks. Psychopharmacology (Berl) (1996) 123:231-8. doi:10.1007/BF02246577.
78. Knott V, McIntosh J, Millar A, Fisher D, Villeneuve C, Ilivitsky V, et al. Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist. Pharmacol Biochem Behav (2006) 85:228-42. doi:10.1016/j.pbb.2006.08.005.
79. Lindgren M, Molander L, Verbaan C, Lunell E, Rosen I. Electroencephalographic effects of intravenous nicotine-a dose-response study. Psychopharmacology (Berl) (1999) 145:342-50. doi:10.1007/s002130051067.
80. Lindgren M, Stenberg G, Rosen I. Effects of nicotine in a bimodal attention task. Neuropsychobiology (1998) 38:42-9. doi:10.1159/000026515.
81. Michel C, Hasenfratz M, Nil R, Battig K. Cardiovascular, electrocortical, and behavioral effects of nicotine chewing gum. Klin Wochenschr (1988) 66(Suppl 11):72-9.
82. Anokhin AP, Vedeniapin AB, Sirevaag EJ, Bauer LO, O'Connor SJ, Kuperman S, et al. The P300 brain potential is reduced in smokers. Psychopharmacology (Berl) (2000) 149:409-13. doi:10.1007/s002130000387.
83. Neuhaus A, Bajbouj M, Kienast T, Kalus P, von Haebler D, Winterer G, et al. Persistent dysfunctional frontal lobe activation in former smokers. Psychopharmacology (Berl) (2006) 186:191-200. doi:10.1007/s00213-006-0366-7.
84. Ascioglu M, Dolu N, Golgeli A, Suer C, Ozesmi C. Effects of cigarette smoking on cognitive processing. Int J Neurosci (2004) 114:381-90. doi:10.1080/00207450490270668.
85. Baldeweg T, Wong D, Stephan KE. Nicotinic modulation of human auditory sensory memory: evidence from mismatch negativity potentials. Int J Psychophysiol (2006) 59:49-58. doi:10.1016/j.ijpsycho.2005.07.014.
86. Dunbar G, Boeijinga PH, Demazieres A, Cisterni C, Kuchibhatla R, Wesnes K, et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (2007) 191:919-29. doi:10.1007/s00213-006-0675-x.
87. Harkrider AW, Hedrick MS. Acute effect of nicotine on auditory gating in smokers and non-smokers. Hear Res (2005) 202:114-28. doi:10.1016/j.heares.2004.11.009.
88. Martin LF, Davalos DB, Kisley MA. Nicotine enhances automatic temporal processing as measured by the mismatch negativity waveform. Nicotine Tob Res (2009) 11:698-706. doi:10.1093/ntr/ntp052.
89. Inami R, Kirino E, Inoue R, Arai H. Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity. Pharmacol Biochem Behav (2005) 80:453-61. doi:10.1016/j.pbb.2005.01.001.
90. Inami R, Kirino E, Inoue R, Suzuki T, Arai H. Nicotine effects on mismatch negativity in nonsmoking schizophrenic patients. Neuropsychobiology (2007) 56:64-72. doi:10.1159/000111536.
91. Knott V, Heenan A, Shah D, Bolton K, Fisher D, Villeneuve C. Electrophysiological evidence of nicotine's distracter-filtering properties in non-smokers. J Psychopharmacol (2011) 25:239-48. doi:10.1177/0269881109348158.
92. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry (1998) 155:1490-501.
93. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res (2005) 76:135-57. doi:10.1016/j.schres.2005.02.010.
94. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry (1986) 143:993-7.
95. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull (1997) 23:247-54. doi:10.1093/schbul/23.2.247.
96. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry (1993) 150:1856-61.
97. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry (2006) 63:630-8. doi:10.1001/archpsyc.63.6.630.
98. Dulude L, Labelle A, Knott VJ. Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia. J Clin Psychopharmacol (2010) 30:541-8. doi:10.1097/JCP.0b013e3181f0c9c6.
99. Fisher DJ, Grant B, Smith DM, Borracci G, Labelle A, Knott VJ. Nicotine and the hallucinating brain: effects on mismatch negativity (MMN) in schizophrenia. Psychiatry Res (2012) 196:181-7. doi:10.1016/j.psychres.2012.01.026.
100. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science (1995) 269:1692-6. doi:10.1126/science.7569895.
101. Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci (2000) 20:66-75.
102. Ji D, Dani JA. Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. J Neurophysiol (2000) 83:2682-90.
103. Gioanni Y, Rougeot C, Clarke PB, Lepouse C, Thierry AM, Vidal C. Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur J Neurosci (1999) 11:18-30. doi:10.1046/j.1460-9568.1999.00403.x.
104. Lambe EK, Picciotto MR, Aghajanian GK. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology (2003) 28:216-25. doi:10.1038/sj.npp.1300032.
105. Radcliffe KA, Fisher JL, Gray R, Dani JA. Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Ann N Y Acad Sci (1999) 868:591-610. doi:10.1111/j.1749-6632.1999.tb11332.x.
106. Levin ED, Bettegowda C, Weaver T, Christopher NC. Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial-arm maze. Pharmacol Biochem Behav (1998) 61:335-40. doi:10.1016/S0091-3057(98)00109-9.
107. Rezvani AH, Levin ED. Nicotinic-glutamatergic interactions and attentional performance on an operant visual signal detection task in female rats. Eur J Pharmacol (2003) 465:83-90. doi:10.1016/S0014-2999(03)01439-0.
108. Ciamei A, Aversano M, Cestari V, Castellano C. Effects of MK-801 and nicotine combinations on memory consolidation in CD1 mice. Psychopharmacology (Berl) (2001) 154:126-30. doi:10.1007/s002130000584.
109. Spitzer RL, Williams JB, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R-Non-Patient Edition (SCID-NP, Version 1.0 with Supplement for DSM-IV). Washington, DC: American Psychiatric Press (1990).
110. Wechsler D. Manual for the Wechsler Adult Intelligence Scale. New York: Psychological Corporation (1955). 110 p.
111. Heatherton T, Kozlowski L, Frecker R, Fagerstrom K. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict (1991) 86:1119-27. doi:10.1111/j.1360-0443.1991.tb01879.x.
112. Kay S, Fiszbein A, Opler L. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull (1987) 13:261-76. doi:10.1093/schbul/13.2.261.
113. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress (1998) 11:125-36. doi:10.1023/A:1024465317902.
114. Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry (2005) 62:985-94. doi:10.1001/archpsyc.62.9.985.
115. Hariharan M, VanNoord T, Greden JF. A high-performance liquid-chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma. Clin Chem (1988) 34:724-9.
116. Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E, et al. Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci (2006) 26:8707-14. doi:10.1523/JNEUROSCI.0546-06.2006.
117. Friedman D, Simpson G, Hamberger M. Age-related changes in scalp topography to novel and target stimuli. Psychophysiology (1993) 30:383-96. doi:10.1111/j.1469-8986.1993.tb02060.x.
118. Cohen JD, Barch DM, Carter C, Servan-Schreiber D. Context-processing deficits in schizophrenia: converging evidence from three theoretically motivated cognitive tasks. J Abnorm Psychol (1999) 108:120-33. doi:10.1037/0021-843X.108.1.120.
119. Gratton G, Coles MG, Donchin E. A new method for off-line removal of ocular artifact. Electroencephalogr Clin Neurophysiol (1983) 55:468-84. doi:10.1016/0013-4694(83)90135-9.
120. Cho HS, Perry EB, Gunduz-Bruce H, D'Souza DC. The ketamine paradigm in humans: relevance to psychotic disorders. In: Heresco-Levy U, Daniel C, Javitt DC, editors. Glutamate in Neuropsychiatric Disorders Trivandrum. Kerala, India: Research Signpost (2008). p. 99-131.
121. Mathalon DH, Ford JM, Pfefferbaum A. Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol Psychiatry (2000) 47:434-49. doi:10.1016/S0006-3223(99)00277-2.
122. Mathalon DH, Ford JM, Rosenbloom M, Pfefferbaum A. P300 reduction and prolongation with illness duration in schizophrenia. Biol Psychiatry (2000) 47:413-27. doi:10.1016/S0006-3223(99)00151-1.
123. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry (1998) 31(Suppl 2):104-9. doi:10.1055/s-2007-979354.
124. Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull (2012) 38:920-6. doi:10.1093/schbul/sbs076.
125. Alain C, Bernstein LJ, Cortese F, Yu H, Zipursky RB. Deficits in automatically detecting changes in conjunction of auditory features in patients with schizophrenia. Psychophysiology (2002) 39:599-606. doi:10.1111/1469-8986.3950599.
126. Devrim-Ucok M, Keskin-Ergen HY, Ucok A. Novelty P3 and P3b in first-episode schizophrenia and chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2006) 30:1426-34. doi:10.1016/j.pnpbp.2006.05.019.
127. Grillon C, Courchesne E, Ameli R, Geyer MA, Braff DL. Increased distractibility in schizophrenic patients. Electrophysiologic and behavioral evidence. Arch Gen Psychiatry (1990) 47:171-9. doi:10.1001/archpsyc.1990.01810140071010.
128. Merrin EL, Floyd TC. P300 responses to novel auditory stimuli in hospitalized schizophrenic patients. Biol Psychiatry (1994) 36:527-42. doi:10.1016/0006-3223(94)90617-3.
129. Daffner KR, Mesulam MM, Holcomb PJ, Calvo V, Acar D, Chabrerie A, et al. Disruption of attention to novel events after frontal lobe injury in humans. J Neurol Neurosurg Psychiatry (2000) 68:18-24. doi:10.1136/jnnp.68.1.18.
130. Daffner KR, Mesulam MM, Scinto LF, Acar D, Calvo V, Faust R, et al. The central role of the prefrontal cortex in directing attention to novel events. Brain (2000) 123(Pt 5):927-39. doi:10.1093/brain/123.5.927.
131. Woods DL, Knight RT. Electrophysiologic evidence of increased distractibility after dorsolateral prefrontal lesions. Neurology (1986) 36:212-6. doi:10.1212/WNL.36.2.212.
132. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry (2000) 57:270-6. doi:10.1001/archpsyc.57.3.270.
133. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) (1999) 145:193-204. doi:10.1007/s002130051049.
134. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, et al. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl) (1998) 135:213-29. doi:10.1007/s002130050503.
135. Ernst M, Heishman SJ, Spurgeon L, London ED. Smoking history and nicotine effects on cognitive performance. Neuropsychopharmacology (2001) 25:313-9. doi:10.1016/S0893-133X(01)00257-3.
136. Lawrence NS, Ross TJ, Stein EA. Cognitive mechanisms of nicotine on visual attention. Neuron (2002) 36:539-48. doi:10.1016/S0896-6273(02)01004-8.
137. Mancuso G, Andres P, Ansseau M, Tirelli E. Effects of nicotine administered via a transdermal delivery system on vigilance: a repeated measure study. Psychopharmacology (Berl) (1999) 142:18-23. doi:10.1007/s002130050857.
138. McClernon FJ, Gilbert DG, Radtke R. Effects of transdermal nicotine on lateralized identification and memory interference. Hum Psychopharmacol (2003) 18:339-43. doi:10.1002/hup.488.
139. Arendash GW, Sanberg PR, Sengstock GJ. Nicotine enhances the learning and memory of aged rats. Pharmacol Biochem Behav (1995) 52:517-23. doi:10.1016/0091-3057(95)00119-H.
140. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) (1998) 138:217-30. doi:10.1007/s002130050667.
141. D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, et al. Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia. Biol Psychiatry (2012) 72:785-94. doi:10.1016/j.biopsych.2012.05.009.